BioAge Labs (BIOA) Receivables - Net (2025 - 2026)
BioAge Labs' (BIOA) quarterly Receivables - Net came in at $709000.0 in Q1 2026, up 96.4% year-on-year from $361000.0 in Q1 2025, and down 7.8% quarter-over-quarter from $769000.0 in Q4 2025.
BioAge Labs (BIOA) Receivables - Net (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Receivables - Net across 2 years of filings, most recently posting $709000.0 for Q1 2026.
- Receivables - Net for Q1 2026 came in at $709000.0, up 96.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $709000.0 (up 96.4% YoY), and the FY2025 annual result was $769000.0, changed N/A from the prior year.
- Receivables - Net came in at $709000.0 for Q1 2026 at BioAge Labs, down from $769000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $769000.0 in Q4 2025 to a low of $361000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | BioAge Labs | 671.19 Mn | 288.00 Mn | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 709,000.00 |
| Mar 31, 2026 | 709,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Mar 31, 2025 | 361,000.00 |